Jiangzhong Pharmaceutical Co Ltd Total Assets
Jiangzhong Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Jiangzhong Pharmaceutical Co Ltd (600750) holds total assets worth CN¥6.74 Billion CNY (≈ $985.94 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Jiangzhong Pharmaceutical Co Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Jiangzhong Pharmaceutical Co Ltd (1993–2025)
Total assets of Jiangzhong Pharmaceutical Co Ltd from 1993 to 2025. This chart illustrates how Jiangzhong Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Jiangzhong Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
Jiangzhong Pharmaceutical Co Ltd - Asset Composition Analysis
Jiangzhong Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Jiangzhong Pharmaceutical Co Ltd total assets breakdown as of December 2025. Jiangzhong Pharmaceutical Co Ltd's total assets of CN¥6.74 Billion consist of 49.8% current assets and 50.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.3% |
| Accounts Receivable | CN¥851.49 Million | 12.4% |
| Inventory | CN¥454.08 Million | 6.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥424.03 Million | 6.2% |
| Goodwill | CN¥52.37 Million | 0.8% |
Asset Composition Trend (1993–2025)
This chart illustrates how Jiangzhong Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Jiangzhong Pharmaceutical Co Ltd (600750) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangzhong Pharmaceutical Co Ltd's current assets represent 49.8% of total assets in 2025, an increase from 32.1% in 1993.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2025, up from 6.4% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is accounts receivable at 12.4% of total assets.
Jiangzhong Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangzhong Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829
|
China | CN¥7.35 Billion |
Jiangzhong Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.68 | 1.69 | 5.82 |
| Quick Ratio | 1.45 | 1.40 | 5.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.20 Billion | CN¥1.23 Billion | CN¥2.89 Billion |
Jiangzhong Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangzhong Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.59 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | CN¥6.88 Billion |
| Market Capitalization | $2.16 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Jiangzhong Pharmaceutical Co Ltd's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jiangzhong Pharmaceutical Co Ltd's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jiangzhong Pharmaceutical Co Ltd (1993–2025)
The table below shows the annual total assets of Jiangzhong Pharmaceutical Co Ltd from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.88 Billion ≈ $1.01 Billion |
+5.73% |
| 2024-12-31 | CN¥6.51 Billion ≈ $952.32 Million |
+1.66% |
| 2023-12-31 | CN¥6.40 Billion ≈ $936.73 Million |
+1.99% |
| 2022-12-31 | CN¥6.28 Billion ≈ $918.41 Million |
+4.65% |
| 2021-12-31 | CN¥6.00 Billion ≈ $877.64 Million |
+21.81% |
| 2020-12-31 | CN¥4.92 Billion ≈ $720.47 Million |
+3.45% |
| 2019-12-31 | CN¥4.76 Billion ≈ $696.42 Million |
+24.69% |
| 2018-12-31 | CN¥3.82 Billion ≈ $558.54 Million |
+13.46% |
| 2017-12-31 | CN¥3.36 Billion ≈ $492.27 Million |
+9.73% |
| 2016-12-31 | CN¥3.07 Billion ≈ $448.62 Million |
+14.47% |
| 2015-12-31 | CN¥2.68 Billion ≈ $391.92 Million |
-19.50% |
| 2014-12-31 | CN¥3.33 Billion ≈ $486.85 Million |
+11.18% |
| 2013-12-31 | CN¥2.99 Billion ≈ $437.88 Million |
-7.32% |
| 2012-12-31 | CN¥3.23 Billion ≈ $472.48 Million |
+24.72% |
| 2011-12-31 | CN¥2.59 Billion ≈ $378.83 Million |
+3.30% |
| 2010-12-31 | CN¥2.51 Billion ≈ $366.71 Million |
+56.86% |
| 2009-12-31 | CN¥1.60 Billion ≈ $233.79 Million |
+0.73% |
| 2008-12-31 | CN¥1.59 Billion ≈ $232.10 Million |
+29.81% |
| 2007-12-31 | CN¥1.22 Billion ≈ $178.80 Million |
-7.33% |
| 2006-12-31 | CN¥1.32 Billion ≈ $192.95 Million |
+14.53% |
| 2005-12-31 | CN¥1.15 Billion ≈ $168.48 Million |
-1.14% |
| 2004-12-31 | CN¥1.16 Billion ≈ $170.41 Million |
+18.00% |
| 2003-12-31 | CN¥986.94 Million ≈ $144.42 Million |
+33.23% |
| 2002-12-31 | CN¥740.78 Million ≈ $108.40 Million |
+15.88% |
| 2001-12-31 | CN¥639.27 Million ≈ $93.55 Million |
-9.77% |
| 2000-12-31 | CN¥708.47 Million ≈ $103.67 Million |
+4.57% |
| 1999-12-31 | CN¥677.53 Million ≈ $99.14 Million |
+60.83% |
| 1998-12-31 | CN¥421.28 Million ≈ $61.65 Million |
+2.25% |
| 1997-12-31 | CN¥412.00 Million ≈ $60.29 Million |
+27.26% |
| 1996-12-31 | CN¥323.76 Million ≈ $47.38 Million |
+200.86% |
| 1995-12-31 | CN¥107.61 Million ≈ $15.75 Million |
+29.28% |
| 1994-12-31 | CN¥83.24 Million ≈ $12.18 Million |
+9.79% |
| 1993-12-31 | CN¥75.82 Million ≈ $11.10 Million |
-- |
About Jiangzhong Pharmaceutical Co Ltd
China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, fritillaria and loquat capsu… Read more